Further insights into the neurobiology of melanin-concentrating hormone in energy and mood balances

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 2, 2006, Pages 211-229

  Hervieu, Guillaume J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antagonist; Anxiety; Depression; Energy regulation; MCH receptor; MCH1R; MCH2R; Melanin concentrating hormone (MCH); Obesity; Stress

Indexed keywords

ANABOLIC AGENT; ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; ANXIOLYTIC AGENT; ATC 0065; ATC 0175; BUSPIRONE; CHLORDIAZEPOXIDE; DEXFENFLURAMINE; DIAZEPAM; FENFLURAMINE; FLUOXETINE; GW 803440; HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; HYPOTHALAMUS HORMONE; MELANIN CONCENTRATING HORMONE; MELANIN CONCENTRATING HORMONE RECEPTOR 1; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; MELANIN CONCENTRATING HORMONE RECEPTOR 2; N (6 DIMETHYLAMINOMETHYL 5,6,7,8 TETRAHYDRO 2 NAPHTHYL) 4' FLUORO 1,1' BIPHENYL 4 CARBOXAMIDE; NEUROPEPTIDE; PAROXETINE; PHENTERMINE; RIMONABANT; SIBUTRAMINE; SNAP 7941; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADIPOSE TISSUE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG PENETRATION; ENERGY BALANCE; EVIDENCE BASED MEDICINE; FOOD INTAKE; HUMAN; HYPERTENSION; LIVER TOXICITY; MENTAL DISEASE; METABOLIC SYNDROME X; MOOD CHANGE; MUSCLE ATROPHY; NEPHROTOXICITY; NEUROBIOLOGY; NONHUMAN; OBESITY; REVIEW; SEXUAL DYSFUNCTION; SIGNAL TRANSDUCTION; SUICIDAL BEHAVIOR; TRANQUILIZING ACTIVITY; WEIGHT REDUCTION;

AFFECT; ANIMALS; EATING; ENERGY METABOLISM; HUMANS; HYPOTHALAMIC HORMONES; MELANINS; NEUROBIOLOGY; PITUITARY HORMONES; RECEPTORS, SOMATOSTATIN;

EID: 33645804830     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.2.211     Document Type: Review

References (188)

1. NAHON JL: The melanin-concentrating hormone: from the peptide to the gene. Crit. Rev. Neurobiol. (1994) 8(4):221-262.
2. BAKER BI: Melanin-concentrating hormone updated: functional considerations. Trends Endocrinol. Metabol. (1994) 5(3):120-126.
3. GRIFFOND B, BAKER BI: Cell and molecular cell biology of melanin-concentrating hormone. Internatl. Rev. Cytol. (2002) 213:233-277.
4. HERVIEU G: Melanin-concentrating hormone functions in the nervous system: food intake and stress. Expert Opin. Ther. Targets (2003) 7(4):495-511.
5. HERVIEU GJ, MOULON L, CHAMBERS JK et al.: The melanin-concentrating hormone. In: Handbook of Chemical Neuroanatomy; Neuropeptide receptors in the CNS. A Bjorklund, T Hokfelt, and MJ Kuhar (Eds.), Elsevier, Amsterdam (2003) 20:31-92.
6. KAWAUCHI H, BAKER BI: Melanin-concentrating hormone signalling systems in fish. Peptides (2004) 10:1577-1584.
7. TAKAHASHI K: Translational medicine in fish-derived peptides: from fish endocrinology to human physiology and diseases. Endocr. J. (2004) 51:1-17.
8. PISSIOS P, MARATOS-FLIER E: Melanin-concentrating hormone: from fish skin to skinny mammals. Trends Endocrinol. Metab. (2003) 5:243-248.
9. SHI Y: Beyond skin color: emerging roles of melanin-concentrating hormone in energy homeostasis and other physiological functions. Peptides (2004) 25(10):1605-1611.
10. ASHIMA RS, OSEI SY: Neurodocrine regulation of appetite and energy balance. Curr. Opin. Endocrinol. Diabetes (2002) 9:215-223.
11. WREN MA, BLOOM SR: How appetite is controlled. Curr. Opin. Endocrinol. Diabetes. (2002) 9:145-151.
12. BERTHOUD H-R: Multiple neural systems controlling food intake and body weight. Neurosci. Behav. Rev. (2002) 26:393-428.
13. FLIER JS: Obesity wars: molecular progress confronts an expanding epidemic. Cell (2004) 116:337-350.
14. OGDEN CL, FLEGAL KM, CARROLL MS, JOHNSON CL: Prevalence and Trends in Overweight Among US Children and Adolescents, 1999-2000. JAMA (2002) 288:1723-1727.
15. FARRINGAN C, PANG K: Obesity market overview. Nat. Rev. (2002) 1:257-261.
16. CARPENTER AJ, HERTZOG DL: Melanin-concentrating hormone receptor antagonists as potential antiobesity agents. Expert Opin. Ther. Patents (2002) 12:1639-1646.
17. COLLINS CA, KYM PR: Prospects for obesity treatment: MCH receptor antagonists. Curr. Opin. Investig. Drugs (2003) 4:386-394.
18. FORRAY C: The MCH receptor family: feeding brain disorders? Curr. Opin. Pharmacol. (2003) 3:1-5.
19. KOWALSKI TJ, MCBRIAR MD: Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity. Expert Opin. Investig. Drugs (2004) 13:1113-1122.
20. GOMORI A, ISHIHARA A, ITO M et al.: Chronic intracerebroventricular infusion of MCH causes obesity in mice. Am. J. Physiol. Endocrinol. Metab. (2003) 284:E583-E588.
21. ITO M, GOMORI A, ISHIHARA A et al.: Characterization of MCH-mediated obesity in mice. Am. J. Physiol. Endocrinol Metab. (2003) 284:E9403-E945.
22. SHIMADA M, TRITOS NA, LOWELL BB, FLIER JS, MARATOS-FLIER E: Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature (1998) 396:670-674.
23. BOUTIN JA, SUPLY T, AUDINOT V et al.: Melanin-concentrating hormone and its receptors: state of the art. Can. J. Physiol. Pharmacol. (2002) 80(5):388-395.
24. BOROWSKY B, DURKIN M, OGOZALER K et al.: Antidepressant, anxiolytic and anorectic properties of MCH-R1 antagonist. Nat. Med. (2002) 8(8):825-830.
25. TAKEKAWA S, ASAMI A, ISHIHARA Y et al.: T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur. J. Pharmacol. (2002) 438(3):129-135.
26. AL-BARAZANJI KA, BARVIAN KR, BIGHAM EC et al.: The discovery of potent and selective MCH receptor-1 antagonists for the treatment of obesity, Proceedings of the 18th International Symposium of Medicinal Chemistry, Copenhagen/Malmo (2004).
27. CARPENTER AJ: Melanin concentrating hormone receptor-1 (MCH-1) antagonists. Proceedings of the 18th International Symposium of Medicinal Chemistry, Copenhagen/Malmo (2004).
28. MASHIKO S, ISHIHARA A, GOMORI A et al.: Anti-obesity Effect of an MCH1R Antagonist in Diet-Induced Obese Mice. Endocrinology (2005) 146(7):3080-3086
29. GEORGESCU D, SEARS RM, HOMMEL JD et al.: The hypothalamic neuropeptide melanin-concentrating hormone acts in the nucleus accumbens to modulate feeding behavior and forced-swim performance. J. Neurosci. (2005) 25:2933-2940.
30. KOWALSKI TJ, FARLEY C, COHEN-WILLIAMS ME, VARTY G, SPAR BD: Melanin-concentrating hormone-1 receptor antagonism decreases feeding by reducing meal size. Eur. J. Pharmacol. (2004) 497(1):41-47.
31. SOUERS AJ, GAO J, BRUNE M et al.: Identification of 2-(4-benzyloxyphenyl)-N-[1-(2-pyrrolidin-1-yl-ethyl) -1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity. J. Med. Chem. (2005) 48:1318-1321.
32. MACBRIAR MD, GUZIK H, XU R et al.: Discovery of bicycloalkyl urea melanin concentrating hormone receptor antagonists: orally efficacious antiobesity therapeutics. J. Med. Chem. (2005) 48(7):2274-2277.
33. MARSH DJ, WEINGARTH DT, NOVI DE et al.: Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc. Natl. Acad. Sci. USA (2002) 99(5):3240-3245.
34. CHEN YY, HU CZ, HSU CK et al.: Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity. Endocrinology (2002) 143(7):2469-2477.
35. SMITH DG, TZAVARA ET, SHAW J et al.: Mesolimbic dopamine supersensitivity in melanin-concentrating hormone-1 receptor-deficient mice. J. Neurosci. (2005) 25:914-922.
36. KOOB GF: Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry (1999) 46:1167-1180.
37. NESTLER EJ, BARROT M, DILEONE RJ, EISCH AJ, GOLD SJ, MONTEGGIA LM: Neurobiology of depression. Neuron (2002) 34:13-25.
38. CHAKI S, FUNAKOSHI T, HIROTA-OKUNO S et al.: Anxiolytic-and antidepressant-like profile of ATC0065 and ATC0175: Nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists. J. Pharmacol. Exp. Ther. (2005) 313(2):831-839.
39. SCHWARTZ MW, GELLING RW: Rats lighten up with MCH antagonist. Nat. Med. (2002) 8(8):779-781.
40. DOGGRELL SA: Does the melanin-concentrating hormone antagonist SNAP-7941 deserve 3As? Expert Opin. Investig. Drugs (2003) 12:1035-1038.
41. QU D, LUDWIG DS, GAMMELTOFT S et al.: A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature (1996) 380:243-244.
42. ROSSI M, BLOOM SR: MCH acutely stimulates feeding, but chronic administration has no effect on body weight. Endocrinology (1997) 138(1):351-355.
43. LUDWIG DS, MOUNTJOY KG, TATO JB et al.: Melanin-concentrating hormone: a functional antagonist in the hypothalamus. Am. J. Physiol. Endocrinol. Metab. (1998) 274(37):E627-E633.
44. DELLA-ZUANA O, PRESSE F, ORTOLA C, DUHAULT J, NAHON JL, LEVENS N: Acute and chronic administration of MCH enhances food intake and body weight in Wistar and Sprague-Dawley rats. Int. J. Obesity (2002) 26:1-7.
45. SEARS RM, GEORGESCU D, MARATOS-FLIER E et al.: The neuropeptide MCH controls feeding and mood via action on the nucleus accumbens shell. Soc. Neurosci. Abstr. (2004) 763.9.
46. WHITLOCK BK, DANIEL JA, MCMAHON CD et al.: Intracerebroventricular melanin-concentrating hormone stimulates food intake in sheep. Domest. Anim. Endocrinol. (2005) 28:224-232.
47. SHEARMAN LP, CAMACHO RE, SLOAN STRIBLING D et al.: Chronic MCH-1 receptor modulation alters appetite, body weight and adiposity in rats. Eur. J. Pharmacol. (2003) 475(1-3):37-47.
48. STRUBBLE JH, VAN DIJK G: The temporal organization of ingestive behaviour and its interactions with regulation of energy balance. Neurosci. Biobevior. Rev. (2002) 26:485-498.
49. BENOIT SC, CLEGG DJ, WOODS SC, SEELEY RJ: The role of previous exposure in the appetitive and consummatory effects of orexigenic neuropeptides. Peptides (2005) 26:751-757.
50. LUDWIG DS, TRITOS N, MASTAITIS JW et al.: MCH overexpression in transgenic mice leads to obesity and insulin resistance. J. Clin. Invest. (2001) 107(3):379-386.
51. BECK B: Ko's and organisation of peptidergic feeding behavior mechanisms. Neurosci. Biobevior. Rev. (2001) 25:143-158.
52. PEREIRA-DA-SILVA M, TORSONI MA, NOURANI HV et al.: Hypothalamic melanin-concentrating hormone is induced by cold exposure. Endocrinology (2003) 144(11):4831-4840.
53. KOKKOTOU E, JEON JY, WANG X et al.: Mice with MCH ablation resist diet induced obesity through strain specific mechanisms. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 289(1):R117-R124.
54. SEGAL-LIEBERMAN G, BRADLEY RL, KOKKOTOU E et al.: Melanin-concentrating hormone is a critical mediator of the leptin-deficient phenotype. Proc. Natl. Acad. Sci. USA (2003) 100(17):10085-10090.
55. BRADLEY RL, MANSFIELD JP, MARATOS-FLIER E: Neuropeptides, including neuropeptide Y and melanocortins, mediate lipolysis in murine adipocytes. Obes. Res. (2005) 13(4):653-661.
56. TRITOS NA, ELMQUIST JK, MASTAITIS, FLIER JS, MARATOS-FLIER E: Characterization of expression of hypothalamic appetite-regulating peptides in obese hyperleptinemic brown adipose tissues-deficient (uncoupling protein-promoter-driven diphteria toxin A) mice. Endocrinology (1998) 139:4634-4641.
57. OLDFIELD BJ, GILES ME, WATSON A, ANDERSON C, COLVILL LM, MACKINLEY MJ: The neurochemical characterization of hypothalamic pathways projecting polysynaptically to brown adipose tissue in the rat. Neuroscience (2002) 110(3):515-526.
58. GAVRILA A, CHAN JL, MILLER LC, HEIST K, YIANNAKOURIS N, MANTZOROS CS: Circulating MCH, AgRP, and alpha-MSH hormone levels in relation to body compositions: alterations in response to food deprivation and recombinant leptin administration. J. Clin. Endocrinol. Metab. (2005) 90(2):1047-1054.
59. TADAYYON M, WELTERS HJ, HAYNES AC, CLUDERAY JE, HERVIEU G: Expression of melanin-concentrating hormone receptors in insulin-producing cells: MCH stimulates insulin release in RINm5F and CRI-G1 cell-lines. Biochem. Biophysic. Res. Com. (2000) 275(2):709-712.
60. BRADLEY RL, KOKKOTOU EG, MARATOS-FLIER E, CHEATAM B: MCH regulates leptin synthesis and secretion in rat adipocytes. Diabetes (2000) 49:1073-1077.
61. BRADLEY RL, MANSFIELD JPR, MARATOS-FLIER E, CHEATAM B: Melanin concentrating hormone activates signaling pathways in 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metabol. (2002) 283(3):E584-E592.
62. MIZUNO TM, KLEOPOULOS SP, BERGEN HT, ROBERTS JL, PRIEST CA, MOBBS CV: Hypothalamic POMC mRNA is reduced by fasting in ob/ob and db/db mice, but is stimulated by leptin. Diabetes (1998) 47:294-297.
63. HUANG Q, VIALE A, PICARD F, NAHON JL, RICHARD D: Effects of leptin on MCH expression in the brain of lean and obese mice. Neuroendocrinology (1999) 69:145-153.
64. MONDAL MS, NAKAZATO M, MATSUKARA S: Characterization of orexins (hypocretins) and melanin-concentrating hormone in genetically obese mice. Reg. Peptides (2002) 104(1-3 Special Issue):21-25.
65. HANADA R, NAKAZATO M, MUTSUKURA S, MURAKAMI N, YOSHIMATI H, SAKATA T: Differential regulation of MCH and orexin genes in the AgRP/MC4 receptor system. Biochem. Biophys. Res. Comm. (2000) 268:88-91.
66. STRICKER-KRONGRAD A, DIMITROV T, BECK B: Central and peripheral dysregulation of melanin-concentrating hormone in obese Zucker rats. Mol. Brain Res. (2001) 92(1-2):43-48.
67. MAEKAWA F, QUAH HM, TANAKA K, OHKI-HAMAZAKI H: Leptin resistance and enhancement of feeding facilitation by melanin-concentrating hormone in mice lacking bombesin receptor subtype-3. Diabetes (2004) 53(3):570-576.
68. ELLIOTT JC, HARROLD JA, BRODIN P et al.: Increases in MCH and MCH receptor levels in the hypothalamus of dietary-obese rats. Brain Res. Mol. Brain Res. (2004) 128(2):150-159.
69. PRESSE F, SOROKOVSKI I, MAX JP, NICOLAIDIS S, NAHON JL: MCH is a potent anorectic peptide regulated by food-deprivation and glucopenia in the rat. Neuroscience (1996) 71(3) 735-745.
70. MORTON GJ, MYSTKOWSKI P, MATSUMOTO AM, SCHWARTZ MW: Increased hypothalamic melanin concentrating hormone gene expression during energy restriction involves a melanocortin-independent, estrogen-sensitive mechanism. Peptides (2004) 25(4):667-74.
71. KNOLLEMA S, BROWN ER, VALE W, SAWCHENKO PE: Novel hypothalamic and preoptic sites of pre-proMCH mRNA and peptide expression in lactating rats. J. Neuroendocrinol. (1992) 4:709-718.
72. SUN G, TIAN Z, MURATA T, NARITA K, HONDA K, HIGUCHI T: Central and peripheral immunoreactivity of MCH in hypothalamic obese and lactating rats. J. Neuroendocrinol. (2004) 16(1):79-83.
73. MYSTKOWSKI P, SEELEY RJ, HAHN TM et al.: Hypothalamic MCH and estrogen-induced weight loss. J. Neurosci. (2000) 20(22):8637-8642.
74. SHIMOKAWA T, KUMA MV, LANE MD: Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides. Proc. Natl. Acad. Sci. USA (2002) 99(1):66-71.
75. ZHOU D, SHEN Z, STRACK AM, MARSH DJ, SHEARMAN LP: Enhanced running wheel activity of both Mch1r- and Pmch-deficient mice. Regul. Pept. (2005) 124(1-3):53-63.
76. ASTRAND A, BOHLOOLY-Y M, LARSDOTTER S et al.: Mice lacking MCH1R demonstrate increased heart rate associated with altered autonomic activity. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2004) 287(4):R749-R758.
77. AUDINOT V, LAHAYE C, SUPLY T et al.: Structurc-activity relationship studies of melanin-concentrating hormone (MCH)-related peptide ligands at SLC-1, the human MCH receptor. J. Biol. Chem. (2001) 276(17):13554-13562.
78. SUPLY T, DELLA-ZUANA O, AUDINOT V et al.: SLC-1 receptor mediates effect of melanin-concentrating hormone on feeding behavior in rat: A structure-activity study. J. Pharmacol. Exp. Therapeut. (2001) 299(1):137-146.
79. BEDNAREK MA, HRENIUK DL, TAN C et al.: Synthesis and biological evaluation in vitro of selective, high affinity peptide antagonists of human melanin-concentrating hormone action at human melanin-concentrating hormone receptor 1. Biochemistry (2002) 41(20):6383-6390.
80. BEDNAREK MA, TAN C, HRENIUK DL et al.: Synthesis and biological evaluation in vitro of a selective, high potency peptide agonist of human melanin-concentrating hormone action at human melanin-concentrating hormone receptor 1. J. Biol. Chem. (2002) 277(16):13821-13826.
81. HAYNES AC, STEVENS AJ, MUIR A et al.: A MCH receptor (SLC-1) antagonist reduces food intake and body weight in rats and mice, North American Association for the Study of Obesity. Proceedings of the NAASO 2001: Obesity: From laboratory investigation to clinical practice. Annual Meeting of the NAASO, Quebec City, Canada, O152.
82. DELLA-ZUANA O, REVEREAULT L, BECK-SICKINGER A, MONGE A, CAIGNARD DH, FAUCHERE JL: A potent and selective NPY Y5 antagonist reduces food intake but not through blockade of the NPY Y5 receptor. Int. J. Obese. (2004) 28:628-639.
83. KOKKOTOU EG, TRITOSNA, MASTAITIS JW, SLIEKER L, MARATOS-FLIER E: Melanin-concentrating hormone receptor is a target of leptin action in the mouse brain. Endocrinology (2001) 142(2):680-686.
84. UNMEHOPA UA, VAN HEERIKHUIZE JJ, SPIJKSTRA W et al.: Increased melanin concentrating hormone receptor Type I in the human hypothalamic infundibular nucleus in cachexia. J. Clin. Endocrinol. Metab. (2005) 90(4):2412-2419.
85. GIBSON WT, PISSIOS P, TROMBLY DJ et al.: Melanin-concentrating hormone receptor mutations and human obesity: functional analysis. Obes. Res. (2004) 12(5):743-749.
86. HAWES BE, GREEN B, O'NEILL K et al.: Identification and characterization of single-nucleotide polymorphisms in MCH-R1 and MCH-R2. Obes. Res. (2004) 12(8):1327-1334.
87. BITTENCOURT JC, PRESSE F, ARIAS C et al.: The melanin-concentrating hormone system of the rat brain: an immuno-and hybridization histochemical characterization. J. Comp. Neurol. (1992) 319:218-245.
88. KNIGGE KM, BAXTER-GRILLO D, SPECIALE J, WAGNER J: Melanotropic peptides in the mammalian brain: the melanin-concentrating hormone. Peptides (1996) 17(6):1063-1073.
89. BERNADIS LL, BELLINGER LL: The lateral hypothalamic area revisited: ingesting behavior. Neurosci. Behav. Rev. (1996) 20(2):189-287.
90. SAWCHENCKO PE: Toward a new neurobiology of energy balance, appetite and obesity. The anatomists weigh-in. J. Comp. Neurol. (1998) 402:435-441.
91. ELMQUIST JK, ELIAS CF, SAPER CB: From lesions to leptin: hypothalamic control of food intake and body weight. Neuron (1999) 22:221-223.
92. FUNAHASHI H, TAKENOYA F, GUAN JL, KAGEYAMA H, YADA T, SHIODA S: Hypothalamic neuronal networks and feeding-related peptides involved in the regulation of feeding. Anat. Sci. Int. (2003) 78:123-138.
93. KING PJ: The hypothalamus and obesity. Curr. Drug Targets (2005) 6:225-240.
94. HERVIEU GJ, CLUDERAY JE, HARRISON D et al.: The distribution of the mRNA and protein products of the melanin-concentrating hormone (MCH) receptor gene, slc-1, in the central nervous system of the rat. Eur. J. Neurosci. (2000) 12:1194-1216.
95. SAITO Y, CHENG M, LESLIE FM, CIVELLI O: Expression of the Melanin-concentrating-hormone receptor mRNA in the rat brain. J. Comp. Neurol. (2001) 435:26-42.
96. LEMBO PMC, GRAZZINI E, CAO J. et al.: The receptor for the orexigenic peptide MCH is a G-protein-coupled receptor. Nature Cell Biol. (1999) 1:267-271.
97. SAPER CB, THOMAS C, CHOU TC, ELMQUIST JK: The need to feed: homeostatic and hedonic control of eating. Neuron (2002) 36:199-211.
98. ZHENG H, CORKERN M, STOYANOVA I, PATTERSON LM, TIAN R, BERTHOUD HR: Peptides that regulate food intake: appetite-inducing accumbens manipulation activates hypothalamic orexin neurons and inhibits POMC neurons. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2003) 284(6):R1436-R1444.
99. STEINIGER TL, KILDUFF TS, BEHAN M, BENCA RM, LANDRY CF: Comparison of hypocretin/orexin and MCH neurons and axonal projections in the embryonic and postnatal rat brain. J. Chem. Neuroanat. (2004) 27(3):165-181.
100. BURDAKOV D, GERASIMENKO O, VERKHRATSKY A: Physiological changes in glucose differentially modulate the excitability of hypothalamic melanin-concentrating hormone and orexin neurons in situ. J. Neurosci. (2005) 25:2429-2433.
101. WILLIAMS G, CAI XJ, ELLIOTT JC, HARROLD JA: Anabolic peptides. Physiol. Behav. (2004) 81(2):211-222.
102. BECK B: Neuropeptides and obesity. Nutrition (2000) 16:916-923.
103. JEANRENAUD B, ROHNER-JEANRENAUD F: Effects of neuropeptides and leptin on nutrient partitioning: dysregulations in obesity. Ann. Rev. Med. (2001) 52:339-351.
104. JEQUIER E: Leptin signaling, adiposity, and energy balance. Ann. NY Acad. Sci. (2002) 967:379-388.
105. GAO XB, GHOSH PK, VAN DEN POLAN: Neurons synthesizing melanin-concentrating hormone identified by selective reporter gene expression after transfection in vitro: transmitter responses. J. Neurophysiol. (2003) 90(6):3978-3985.
106. ABBOTT CR, KENNEDY AR, WREN AM et al.: Identification of hypothalamic nuclei involved in the orexigenic effect of melanin-concentrating hormone. Endocrinology (2003) 144(9):3943-3949.
107. MERCER JG, SPEAKMAN JR: Hypothalamic neuropeptide mechanisms for regulating energy balance: from rodent models to human obesity. Neurosci. Biobevior. Rev. (2001) 25:101-116.
108. STANLEY BG: Glutamate and its receptors in lateral hypothalamic stimulation of eating. In: Drugs receptor subtypes and ingestive behaviour. Cooper SJ and Clifton PJ (Eds.), Academic Press, London (1996):301-322.
109. CLAPHAM JC, ARCH JRS, TADAYYON M: Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacol. Ther. (2001) 89:81-121.
110. ABRAHAMSON EE, LEAK RK, MOORE RY: The suprachiasmatic nucleus projects to posterior hypothalamic arousal systems. Neuroreport (2001) 12(2):435-440.
111. VAN DEN POL AN, ACUNA-GOYCOLEA C, CLARK KR, GHOSH PK: Physiological properties of hypothalamic MCH neurons identified with selective expression of reporter gene after recombinant virus infection. Neuron (2004) 42(4):635-652.
112. COLLIN M, BACKBERG M, OVESJO ML et al.: Plasma membrane and vesicular glutamate transporter mRNAs/proteins in hypothalamic neurons that regulate body weight. Eur. J. Neurosci. (2003) 18(6):1265-1278.
113. COMPAGNONE N, FELLMANN D: Implication of NMDA receptors in glutamate-induced MCH secretion. Neuroreport (1993) 5(3):231-232.
114. BACKBERG M, COLLIN M, OVESJO ML, MEISTER B: Chemical coding of GABA (B) receptor immunoreactive neurones in hypothalamic regions regulating body weight. J. Neuroendocrinol. (2003) 15(1):1-14.
115. MORADES N, CIOFI P, LAFON P, TRAMU G, GARRET M: GABA (A) receptor epsilon subunit expression in identified peptidergic neurones of rat hypothalamus. Brain Res. (2003) 967(1-2):285-289.
116. BACKBERG M, ULTENIUS C, FRITSCHY JM, MEISTER B: Cellular localisation of GABA receptor alpha subunit immunoreactivity in the rat hypothalamus: relationship with neurones containing orexigenic or anorexigenic peptides. J. Neuroendocrinol. (2004) 16(7):589-604.
117. MALDONADO-IRIZARRY CS, SWANSON CJ, KELLEY AE: Glutamate receptors in the nucleus accumbens shell control feeding via the lateral hypothalamus. J. Neurosci. (1995) 15:6779-6788.
118. GAO XB, VAN DEN POL AN: Melanin concentrating hormone depresses synaptic activity of glutamate and GABA neurons from rat lateral hypothalamus. J. Physiol. (2001) 533:237-252.
119. COTA D, MARSICANO G, TSCHOP M et al.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. (2003) 112(3):423-431.
120. TRITOS NA, SEGAL-LIEBERMAN G, VEZERIDIS PS, MARATOS-FLIER E: Estradiol-induced anorexia is independent of leptin and melanin-concentrating hormone. Obes. Res. (2004) 12(4):716-724.
121. DALLVECHIA-ADAMS S, KUHAR MJ, SMITH Y: Cocaine- and amphetamine-regulated transcript peptide projections in the ventral midbrain: colocalization with gamma-aminobutyric acid, melanin-concentrating hormone, dynorphin, and synaptic interactions with dopamine neurons. J. Comp. Neurol. (2002) 448(4):360-372.
122. FEKETE C, WITTMANN, LIPOSITS Z, LECHAN RM: Origin of cocaine-and amphetamine-regulated transcript (CART)-immunoreactive innervation of the hypothalamic paraventricular nucleus. J. Comp. Neurol. (2004) 469(3):340-350.
123. CVETKOVIC V, BRISCHOUX F, JACQUEMARD C, FELLMANN D, GRIFFOND B, RISOLD PY: Characterization of subpopulations of neurons producing melanin-concentrating hormone in the rat ventral diencephalon. J. Neurochem. (2004) 91(4):911-919.
124. FETISSOV SO, HUANG P, ZHANG Q et al.: Expression of hypothalamic neuropeptides after acute TCDD treatment and distribution of Ah receptor repressor. Regul. Pept. (2004) 119(1-2):113-124.
125. BUIJS RM, CHUN SJ, NIIJIMA A, ROMINJ HJ, NAGAI K: Parasympathetic and sympathetic control of the pancreas: a role for the suprachiasmatic nucleus and other hypothalamic centers that are involved in the regulation of food intake. J. Comp. Neurol. (2001) 431(4):405-423
126. BJURSELL M, EGECIOGLU E, GERDIN AK et al.: Importance of MCH receptor for the acute effect of ghrelin. Biochem. Biophysis. Res. Comm. (2005) 326(4):759-785.
127. BLUET-PAJOT MT, PRESSE F, VOKO Z et al.: Neuropeptide E-I antagonises the action of melanin-concentrating hormone on stress-induced release of adrenocorticotropin in the rat. J. Neuroendocrinol. (1995) 7:297-303.
128. JEZOVA D, BARTANUTZ V, WESTERGREN I et al.: Rat melanin-concentrating hormone stimulates adrenocorticotropin secretion: evidence for a site of action in brain regions protected by the blood brain barrier. Endocrinology (1992) 130:1021-1029.
129. ASHMEADE TE, JONES DNC, MUNTON et al.: An investigation into the effect of MCH on neuroendocrine markers in the rat. Eur. J. Neurosci. (2000) 12(Suppl. 11) 217(2):476.
130. KENNEDY AR, TODD JF, DHILLO WS et al.: Effect of injection of melanin-concentrating hormone into the paraventricular nucleus: further evidence for a stimulatory role in adrenal axis. J. Neuroendocrinol. (2003) 15(3):268-272.
131. PARKES DG, RIVEST S, RIVIER C, SAWCHENKO PE, VALE W: MCH and NEI activate hypothalamic CRF neurons in conscious rats. Proceedings of the Society of Neuroscience, San Diego, USA (1992) 18, 56(3):120.
132. PARKES DG, VALE W: Secretion of Melanin-concentrating hormone and neuropeptide-EI from cultured rat hypothalamic cells. Endocrinology (1992) 131:1826-1831.
133. DRAZEN DL, COOLEN LM, STRADER AD, WORTMAN MD, WOODS SC, SEELEY RJ: Differential effects of adrenalectomy on melanin-concentrating hormone and orexin A. Endocrinology (2004) 145:3404-3412.
134. SECKL JR: Prenatal glucorticoids and long-term programming. Eur. J. Endocrinol. (2004) 151(Supl. 3):U49-U62.
135. LEVIN BE: Metabolic imprinting on genetically predisposed neural circuits perpetuates obesity. Nutrition (2000) 16:909-915.
136. ELMQUIST JK, FLIER JS: The fat brain axis enters a new dimension. Science (2004) 304:63-64.
137. DAVIDOWA H, LI Y, PLAGEMANN A: Altered responses to orexigenic (AGRP, MCH) and anorexigenic (alpha-MSH, CART) neuropeptides of paraventricular hypothalamic neurons in early postnatally overfed rats. Eur. J. Neurosci. (2003) 18(3):613-621.
138. PRESSE F, HERVIEU G, IMAKI T, SAWCHENKO PE, VALE W, NAHON JL: Rat melanin-concentrating hormone messenger ribonucleic acid expression: marked changes during development and after stress and glucocorticoid stimuli, Endocrinology (1992) 131:1241-1250.
139. KELLENDONK C, EIDEN S, KRETZ O et al.: Inativation of the GR in the nervous system affects energy accumulation. Endocrinology (2002) 14(6):2333-2340.
140. PEEKE PM, CHROUSOS GP: Hypercortisolism et obesity. Stress: basic mechanisms and clinical implications. Ann. NY Acad Sci., NY (1995) 711:665-676.
141. KENNEDY AR, TODD JF, STANLEY SA et al.: Melanin-concentrating hormone (MCH) suppresses thyroid stimulating hormone (TSH) release, in vivo and in vitro, via the hypothalamus and the pituitary. Endocrinology (2001) 142(7):3265-3268.
142. GONZALEZ MI, VAZIRI S, WILSON CA: Behavioral effects of alpha-MSH and MCH after central administration in the female rat. Peptides (1996) 17(1):171-177.
143. MONZON ME, VARAS MM, DE BARIGLIO SR: Anxiogenesis induced by nitric oxide synthase inhibition and anxiolytic effect of melanin-concentrating hormone (MCH) in rat brain. Peptides (2001) 22(7):1043-1047.
144. KELA J, SALMI P, RIMONDINI-GIORGINI R, HEILIG M, WAHLESTEDT C: Behavioural analysis of melanin-concentrating hormone in rats: evidence for orexigenic and anxiolytic properties. Regul. Pept. (2003) 114:109-114.
145. MATTHEWS K, ROBBINS TW: Early experience as a determinant of adult behavioural responses to reward: the effects of repeated maternal separation in the rat. Neurosci. Biobehav. Rev. (2003) 27(1-2):45-55.
146. SAITO Y, NOTHACKER HP, CIVELLI O: Melanin-concentrating-hormone receptor: an orphan receptor fits the key. Trends Endocrinol. Metabol. (2000) 11(8):299-303.
147. GONZALEZ MI, KALIA V, HOLE DR, WILSON CA: α-MSH and MCH modify monoaminergic levels in the preoptic area of the rat. Peptides (1997) 18(3):387-392.
148. LI X, WITKIN JM, NEED AB, SKOLNICK: Enhancement of antidepresaant properties by a potentiator of AMPA receptors. Mol. Cell. Neurobiol. (2003) 23(3):419-430.
149. CAIRNS LIZ: Update analysis, therapy analysis, obesity. Pharmaprojects (2003) 23(10):1-3.
150. ELMQUIST JK: Hypothalamic pathways underlying the endocrine, autonomic, and behavioral effects of leptin. Physiol. Behav. (2001) 74:703-708.
151. HOCKFELT T, BARTFAI T, BLOOM F: Neuropeptides: opportunities for drug discovery. Lancet Neurol. (2003) 2(8):463-472.
152. XU YL, JACKSON VR, CIVELLI O: Orphan G protein-coupled receptors and obesity. Eur. J. Pharmacol. (2004) 500:243-253.
153. BAYS HE: Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes. Res. (2004) 12:1197-1211.
154. MASTORAKOS G, ZAPANTI E: The hypothalamic-pituitary-adrenal axis in the neuroendocrine regulation of food intake and obesity: the role of corticotropin releasing hormone. Nutr. Neurosci. (2004) 7:271-280.
155. BJORNSTROP P, ROSMOND R: Obesity and cortisol. Nutrition (2000) 16:924-936.
156. RESSLER KJ, NEMEROOF CB: Role of 5-HT and noadrenergic systems in the pathophysiology of depression and anxiety disorders. Depress. Anxiety (2000) 12(Suppl. 1):2-19.
157. PACHER P, KECSKEMETI V: Trends in the development of new antidepressants. Is there a light at the end of the tunnel? Curr. Med. Chem. (2004) 11:925-943.
158. BOSQUER FJ, WESTERLINK BH, CREMERS TI et al.: Future antidepressants: what is the pipeline and what is missing. CNS Drugs (2004) 18(11):705-732.
159. LOWRY CA: Functional subsets of serotonergic neurones: implications for control of the hypothalamic-pituitary adrenal axis. J. Neuroendocrinol. (2002) 14(11):911-923.
160. HANLEY NR, VAN DE KAR LD: Serotonin and the neuroendocrine regulation of the hypothalamic-pituitary-adrenal axis in health and disease. Vitam. Horm. (2003) 66:189-255.
161. DILEONE RJ, GEORGESCU D, NESTLER EJ: Lateral hypothalamic neuropeptides in reward and drug addiction. Life Sci. (2003) 73:759-768.
162. CARR KD: Augmentation of drug reward by chronic food restriction: behavioral evidence and underlying mechanisms. Physiol. Behav. (2002) 76(3):353-364.
163. KELLEY AE, BERRIDGE KC: The neuroscience of natural rewards: relevance to addictive drugs. J. Neurosci. (2002) 22:3306-3311.
164. YANG SC, SHIEHT KR: Differential effects of melanin concentrating hormone on the central dopaminergic neurons induced by the cocaine- and amphetamine-regulated transcript peptide. J. Neurochem. (2005) 92(3):637-646.
165. YANG SC, SHIEHT KR: Effects of the cocaine- and amphetamine-regulated transcript peptide on the turnover of dopamine in tuberoinfundibular neurons and serum prolactin levels: studies using estrogen, melanin concentrating hormone, and melanocortin. Neuropharmacology (2004) 47(7):1070-1080.
166. KOROTKOVA TM, SERGEEVA OA, ERIKSSON KS, HAAS HL, BROWN RE: Excitation of ventral tegmental area dopaminergic and non dopaminergic neurones by orexins/hypocretins. J. Neurosci. (2003) 23(7):7-11.
167. GEORGESCU D, ZACHARIOU V, BARROT M et al.: Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J. Neurosci. (2003) 23(8):3106-3111.
168. VALJENT E, PAGES C, HERVE D et al.: Addictive and non-addictive drugs induce distinct and specific patterns of ERK activation in mouse brain. Eur. J. Neurosc. (2004) 19:1826-1836.
169. PISSIOS P, TROMBLY DJ, TZAMELI I, MARATOS-FLIER E: Melanin-concentrating hormone receptor 1 activates extracellular signal-regulated kinase and synergizes with G(s)-coupled pathways. Endocrinology (2003) 144(8):3514-3523.
170. TRITOS NA, MARATOS-FLIER E: Two important systems in energy homeostasis: melanocortins and MCH. Neuropeptides (1999) 33(5):339-349.
171. THIELE TE, NAVARRO M, SPARTA DR, FEE JR, KNAPP DJ, CUBERO I: Melanocortins and opiate addiction. Life Sci. (1997) 61(1):1-9.
172. MILLER CL, HRUBY VJ, MATSUNAGA TO, BICKFORD PC: Alpha-MSH and MCH are functional antagonists in a CNS auditory gating paradigm. Peptides (1990) 14:31-440.
173. BOHLOOLY-Y M, MAHLAPUU M, ANDERSÉN H et al.: Osteoporosis in MCHR1-deficient mice. Biochem. Biophys. Res. Commun. (2004) 318(4):964-969.
174. VARAS MM, PEREZ MF, RAMIREZ OA, DE BAROGLIO SR: Increased susceptibility to LTP generation and changes in NMDA-NR1 and -NR2B subunits mRNA expression in rat hippocampus after MCH administration. Peptides (2003) 24(9):1403-1411.
175. GULPINAR MA, YEGEN BC: The physiology of learning and memory: role of peptides and stress. Curr. Protein Pept. Sci. (2004) 5(6):457-473.
176. VERRET L, GOUTAGNY R, FORT P et al.: A role for MCH-producing neurones in the central regulation of paradoxical sleep. BMC Neurosci. (2003) 4(1):19.
177. BAYER L, EGGERMANN E, SERAFIN M et al.: Opposite effects of noradrenaline and acetylcholine upon hypocretin/orexin versus melanin concentrating hormone neurons in rat hypothalamic slices. Neuroscience (2005) 130:807-811.
178. BANISADR G, SKRZYDELSKI D, KITABGI P, ROSTENE W, PARSADANIANTZ SM: Highly regionalized distribution of stromal cell-derived factor-1/CXCL12 in adult rat brain: constitutive expression in cholinergic, dopaminergic and vasopressinergic neurons. Eur. J. Neurosci. (2003) 18(6):1593-1606.
179. GUYON A, BANISADR G, ROVERE C et al.: Complex effects of stromal cell-derived factor-1 alpha on melanin-concentrating hormone neuron excitability. Eur. J. Neurosci. (2005) 21:701-710.
180. ARIENZO R, CLARK DE, CRAMP S et al.: Structure-activity relationships of a novel series of melanin-concentrating hormone (MCH) receptor antagonists. Bioorg. Med. Chem. Lett. (2004) 14(15):4099-4102.
181. CLARK DE, HIGGS C, WREN SP et al.: A virtual screening approach to finding novel and potent antagonists at the
182. SOUERS AJ, WODKA D, GAO J et al.: Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg. Med. Chem. Lett. (2004) 14(19):4873-4877.
183. VASUDEVAN A, WODKA D, VERZAL MK, SOUERS AJ et al.: Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 2. Bioorg. Med. Chem. Lett. (2004) 14(19):4879-4882.
184. SOUERS AJ, GAO J, WODKA D et al.: Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Bioorg. Med. Chem. Lett. (2005) 15(11):2752-2757.
185. RECEVEUR JM, BJURLING E, ULVEN T, LITTLE PB, NØRREGAARD PK, HÖGBERG T: 4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists. Bioorg. Med.
186. LAVRADOR K, MURPHY B, SAUNDERS J, STRUTHERS S, WANG X, WILLIAMS J: A screening library for peptide activated G-protein coupled receptors. 1. The test set. J. Med. Chem. (2004) 47(27):6864-6874.
187. SU J, MCKITTRICK BA, TANG H et al.: Discovery of melanin-concentrating hormone receptor R1 antagonists using high-throughput synthesis. Bioorg. Med. Chem. (2005) 13:1829-1836.
188. WITTY DR, HADLEY MS, HERVIEU GJ et al.: Biphenyl carboxamide antagonists of the human melanin-concentrating hormone receptor 11CBy (SLC-1); discovery and SAR. Proceedings of the International Medicinal Chemistry Symposium, Barcelona, Spain (2002).